At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09969 INNOCARE
Market Closed 09-18 16:08:32
14.710
-0.380
-2.52%
High15.400Low14.670Vol9.38M
Open15.150D1 Closing15.090Amplitude4.84%
Mkt Cap25.99BTradable Cap21.98BTotal Shares1.77B
T/O139.09MT/O Rate0.63%Tradable Shares1.49B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
InnoCare Issues 0.58 Million New RMB Shares Under 2024 Incentive Scheme; Hong Kong Share Count Unchanged
Bulletin Express  ·  09-17 17:06
InnoCare Issues 0.58 Million New RMB Shares Under 2024 Incentive Scheme; Hong Kong Share Count Unchanged
Hong Kong Stocks Recover as WCLC Conference Sparks Biotech Rally, While US AI Slowdown Calls Raise Questions
Stock News  ·  09-14
Hong Kong Stocks Recover as WCLC Conference Sparks Biotech Rally, While US AI Slowdown Calls Raise Questions
Hong Kong Stocks Close Mixed as Healthcare Advances, Memory Shares Slump
Deep News  ·  09-14
Hong Kong Stocks Close Mixed as Healthcare Advances, Memory Shares Slump
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
Stock News  ·  09-14
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
Movement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials
Market Focus  ·  09-14
Movement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials
Hong Kong Stock Market Moves | INNOCARE (09969) Surges Over 5% as Its PSMA/STEAP1 Bispecific ADC ICP-B381 Receives Clinical Trial Approval
Stock News  ·  09-14
Hong Kong Stock Market Moves | INNOCARE (09969) Surges Over 5% as Its PSMA/STEAP1 Bispecific ADC ICP-B381 Receives Clinical Trial Approval
Movement Alert｜INNOCARE Falls 5.73% in Regular Trading, Biotech Sector Broadly Weak as National Insurance Negotiation Concludes
Market Focus  ·  09-10
Movement Alert｜INNOCARE Falls 5.73% in Regular Trading, Biotech Sector Broadly Weak as National Insurance Negotiation Concludes
InnoCare Gets First Half of Remaining Stake Bought in Subsidiary
MT Newswires Live  ·  09-08
InnoCare Gets First Half of Remaining Stake Bought in Subsidiary
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Stock News  ·  09-07
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market
Deep News  ·  09-04
Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market
Movement Alert｜INNOCARE Rises 5.48% in Regular Trading, Multiple Institutions Issue Buy Ratings Amid Strong H1 Earnings
Market Focus  ·  09-04
Movement Alert｜INNOCARE Rises 5.48% in Regular Trading, Multiple Institutions Issue Buy Ratings Amid Strong H1 Earnings
Party Time: Brokers Just Made Major Increases To Their InnoCare Pharma Limited (HKG:9969) Earnings Forecasts
Simply Wall St.  ·  08-30
Party Time: Brokers Just Made Major Increases To Their InnoCare Pharma Limited (HKG:9969) Earnings Forecasts
Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales
Stock News  ·  08-28
Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales
InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn
Simply Wall St.  ·  08-28
InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn
InnoCare Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St.  ·  08-27
InnoCare Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
Stock News  ·  08-25
Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals
InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists
Simply Wall St.  ·  08-25
InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists
Movement Alert｜INNOCARE Rises 5.08% in Regular Trading, H1 Earnings Show Return to Profitability with Revenue Up 55.5%
Market Focus  ·  08-25
Movement Alert｜INNOCARE Rises 5.08% in Regular Trading, H1 Earnings Show Return to Profitability with Revenue Up 55.5%
Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
Dow Jones  ·  08-24
Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
InnoCare Pharma Returns to Profit in H1
MT Newswires Live  ·  08-24
InnoCare Pharma Returns to Profit in H1

Introduction

Company Name.
INNOCARE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.
Issue price:
--